Lupin has received approval for its Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, from the United States Food and Drug Administration (USFDA). The company’s Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is the generic version of Omidria Intraocular Solution, 1%/0.3%, of Omeros Corporation (Omeros).
Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement. Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, had annual sales of approximately $42.8 million in the US (IQVIA MAT March 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
